spacer
home > pmps > winter 2019 > a closer look at child-resistant packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Closer Look at Child-Resistant Packaging

Child-resistant (CR) packaging is that which is designed or constructed to be significantly difficult for young children to open or gain access to the contents within a reasonable time and not difficult for normal adults to use properly. Child-resistant packaging can be as well reclosable as non-reclosable, and the child-proof fastenings can also be classified according to their type:

• The closure is incomprehensive for children, because two movements are needed at the same time (for instance, push-turn caps and squeeze-turn caps)
• The closure is unreachable for children, because, for example, it is too large for a child’s hand
• The closure must be opened with a force too strong for a child

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cedric Dujardin is an Analyst Consultant of child resistant packaging at the Belgian Packaging Institute (IBE-BVI).
spacer
Cedric Dujardin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement